



Tests you can trust

Name : Manasa Anupa (28Y/F)

Date : 14 Jan 2025

Test Asked : T3-T4-Ustsh, Quadruple Marker Second Trimester 14-22 Week

Report Status: Complete Report



First National Diagnostic Chain to have
100% of its Labs with NABL Accreditation[#]



98% Reports
released within
06 Hours
of sample reaching the lab⁺



9 out of 10 Doctors Trust
that Thyrocare
reports are
Accurate & Reliable*



1200+
Tests & Profiles



Temperature-
Controlled
Sample Logistics



Unique Barcode
Tracking



Fully Automated
Machines Inspected
Daily



Abnormal Values
Re-Checked Twice



Reports Verified By Expert
MD Pathologists Stationed
at Every Lab



Your reports are digitally verifiable

Scan the QR code inside the report to check authenticity
of reported values

QR code will remain active for 30 days from report release date

Accredited by



NABL From 2005



ISO 9001: 2015 – From 2015



CAP From 2007

PROCESSED AT :

Thyrocare
D-37/1,TTC MIDC,Turbhe,
Navi Mumbai-400 703



📍 Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703 📞 9870666333 ✉ wellness@thyrocare.com

First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation[#]

NAME
REF. BY
TEST ASKED

: MANASA ANUPA (28Y/F)
: DR VISHWA BHARATHI MBBS DGO
: T3-T4-USTSH,QUADRUPLE MARKER SECOND TRIMESTER 14-22 WEEK

SAMPLE COLLECTED AT :
(5053270516),BHAVITHA LABORATORY,DR. MD SHANKAR LINE, OPP OLD SAI HOSPITAL, ARAVIND NAGAR, JAGTIAL, TELANGANA,505327

Report Availability Summary

Note: Please refer to the table below for status of your tests.

✔ 2 Ready

🟡 0 Ready with Cancellation

🔄 0 Processing

✖ 0 Cancelled in Lab

TEST DETAILS	REPORT STATUS
T3-T4-USTSH	Ready ✔
QUADRUPLE MARKER SECOND TRIMESTER 14-22 WEEK	Ready ✔

PROCESSED AT :

Thyrocare

D-37/1, TTC MIDC, Turbhe,
Navi Mumbai-400 703



Tests you can trust

Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703 9870666333 wellness@thyrocare.com

First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation[#]

NAME : MANASA ANUPA (28Y/F)

REF. BY : DR VISHWA BHARATHI MBBS DGO

TEST ASKED : T3-T4-USTSH, QUADRUPLER MARKER SECOND TRIMESTER
14-22 WEEK

SAMPLE COLLECTED AT :

(5053270516), BHAVITHA LABORATORY, DR. MD
SHANKAR LINE, OPP OLD SAI HOSPITAL, ARAVIND
NAGAR, JAGTIAL, TELANGANA, 505327

Summary Report

Tests outside reference range

TEST NAME	OBSERVED VALUE	UNITS	Bio. Ref. Interval.
THYROID			
TOTAL THYROXINE (T4)	14	µg/dL	4.8-12.7
TOTAL TRIIODOTHYRONINE (T3)	208	ng/dL	80-200

Disclaimer: The above listed is the summary of the parameters with values outside the BRI. For detailed report values, parameter correlation and clinical interpretation, kindly refer to the same in subsequent pages.

PROCESSED AT :

Thyrocare

D-37/1,TTC MIDC,Turbhe,
Navi Mumbai-400 703



Tests you can trust

Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703 9870666333 wellness@thyrocare.com

First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation[#]

NAME : MANASA ANUPA (28Y/F)
REF. BY : DR VISHWA BHARATHI MBBS DGO
TEST ASKED : QUADRUPLE MARKER SECOND TRIMESTER 14-22
WEEK,T3-T4-USTSH

SAMPLE COLLECTED AT :
(5053270516),BHAVITHA LABORATORY,DR. MD
SHANKAR LINE, OPP OLD SAI HOSPITAL, ARAVIND
NAGAR, JAGTIAL, TELANGANA,505327

TEST NAME	TECHNOLOGY	VALUE	UNITS
INHIBIN A	C.L.I.A	267.1	pg/mL

Bio. Ref. Interval. :-

Normal cycling females (Days from LH surge)

Early Follicular Phase (-14 to - 10)	1.8 - 17.3
Mid Follicular Phase (-9 to - 4)	3.5 - 31.7
Late Follicular Phase (-3 to - 1)	9.8 - 90.3
Mid cycle (Day 0, LH surge)	16.9- 91.8
Early Luteal Phase (1 to 3)	16.1- 97.5
Mid Luteal Phase (4 to 11)	3.9 - 87.7
Late Luteal Phase (12 to 14)	2.7 - 47.1

Postmenopausal females	< 1.0 - 2.1
Males	< 1.0 - 2

Clinical Significance :

Inhibin A level is used as an endocrine marker for androgen production and monitoring ovarian function .These levels are also used in maternal serum quadruple screening test,to estimate the chance of having birth defects in baby.Increased levels of Inhibin A are related to many conditions in placenta like infection ,hypoxia and placental malformations.

Specifications: Precision: Intra assay (%CV): 4.17 %, Inter assay (%CV):4.28%; Sensitivity: < 1 pg/mL.

Kit Validation References:

Burger HG Evidence for a negative feedback role of inhibin in folliclestimulating hormone regulation in women 1993:1-2:129-32

Please correlate with clinical conditions.

Method:- SEQUENTIAL TWO-STEP IMMUNOENZYMATIC (SANDWICH) ASSAY

Sample Collected on (SCT) : 13 Jan 2025 20:47
Sample Received on (SRT) : 15 Jan 2025 01:20
Report Released on (RRT) : 15 Jan 2025 18:41
Sample Type : SERUM
Labcode : 1401002947/A4564
Barcode : CY002739



Renuka

Dr Renuka MD(Path)

Arshiya

Dr Arshiya MD(Path)

PROCESSED AT :**Thyrocare**D-37/1,TTC MIDC,Turbhe,
Navi Mumbai-400 703

Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703 9870666333 wellness@thyrocare.com

First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation[#]

NAME : MANASA ANUPA (28Y/F)
REF. BY : DR VISHWA BHARATHI MBBS DGO
TEST ASKED : QUADRUPLE MARKER SECOND TRIMESTER 14-22
WEEK,T3-T4-USTSH

SAMPLE COLLECTED AT :
(5053270516),BHAVITHA LABORATORY,DR. MD
SHANKAR LINE, OPP OLD SAI HOSPITAL, ARAVIND
NAGAR, JAGTIAL, TELANGANA,505327

TEST NAME	TECHNOLOGY	VALUE	UNITS
ALPHA FETO PROTEIN	E.C.L.I.A	23.7	IU/mL

Bio. Ref. Interval. :-

Men: 0.5 - 5.5 IU/ml

Non-Pregnant Women: 0.5 - 5.5 IU/ml Pregnancy:

Week Range

14th : 10.41 - 49.40

15th : 13.11 - 57.08

16th : 15.12 - 64.45

17th : 17.72 - 76.11

18th : 19.26 - 91.51

19th : 23.26 - 101.80

20th : 28.05 - 125.85

21st : 33.30 - 92.75

Clinical Significance:

AFP has been used as a cancer marker. AFP testing during pregnancy in combination with Beta HCG and E3, Is recommended as an effective way to determine potential fetal risk of open neural tube defect (NTD).

Specifications: Precision: Intra assay (%CV): 4.1, Inter assay (%CV): 4.2, Sensitivity: 1.5 IU/mL

References : Kaur G, Srivastav J, Sharma S, Huria A, Goel P, Chavan BS. Maternal serum median levels of alpha-foetoprotein, human chorionic gonadotropin & unconjugated estriol in second trimester in pregnant women from north-west India. Indian J Med Res. 2013;138(1):83-8.

Please correlate with clinical conditions.

Method:- SANDWICH ELECTROCHEMILUMINESCENCE IMMUNOASSAY

Sample Collected on (SCT) : 13 Jan 2025 20:47
Sample Received on (SRT) : 15 Jan 2025 01:20
Report Released on (RRT) : 15 Jan 2025 18:41
Sample Type : SERUM
Labcode : 1401002947/A4564
Barcode : CY002739

Dr Renuka MD(Path)

Dr Arshiya MD(Path)

PROCESSED AT :**Thyrocare**D-37/1,TTC MIDC,Turbhe,
Navi Mumbai-400 703

Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703 9870666333 wellness@thyrocare.com

First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation[#]

NAME : MANASA ANUPA (28Y/F)
REF. BY : DR VISHWA BHARATHI MBBS DGO
TEST ASKED : QUADRUPLE MARKER SECOND TRIMESTER 14-22
 WEEK,T3-T4-USTSH

SAMPLE COLLECTED AT :
 (5053270516),BHAVITHA LABORATORY,DR. MD
 SHANKAR LINE, OPP OLD SAI HOSPITAL, ARAVIND
 NAGAR, JAGTIAL, TELANGANA,505327

TEST NAME	TECHNOLOGY	VALUE	UNITS
BETA HCG	E.C.L.I.A	40360	mIU/mL

Bio. Ref. Interval. :-

Men : <2.6 mIU/mL Post menopausal women : <8.3 mIU/mL Non pregnant premenopausal women : <5.3 mIU/mL
 Weeks of gestation Ranges

Week	Range	Week	Range
3rd	: 5.8-71.2	10th	: 46509-186977
4th	: 9.5-750	12th	: 27832-210612
5th	: 217-7138	14th	: 13950-62530
6th	: 158-31795	15th	: 12039-70971
7th	: 3697-163563	16th	: 9040-56451
8th	: 32065-149571	17th	: 8175-55868
9th	: 63803-151410	18th	: 8099-58176

Clinical Significance: The rapid rise in HCG Serum levels after conception makes it an excellent marker for early confirmation and monitoring of pregnancy. HCG levels can be useful in prediction of spontaneous abortions, Aiding in the detection of ectopic pregnancy and multiple gestation. For diagnostic purpose, Results should always be assessed in conjunction with the patients medical history, clinical examination and other findings.

Specifications: Precision: Intra assay (%CV): 4.2, Inter assay (%CV): 6.3, Sensitivity: <= 0.200 mIU/mL

Reference : Schwarz S, Berger P, Wick G. The Antigenic Surface of Human Chorionic Gonadotropin as Mapped by Murine Monoclonal Antibodies.
 Endocrinology 1986;118(1):189-197

Please correlate with clinical conditions.

Method:- SANDWICH ELECTROCHEMILUMINESCENCE IMMUNOASSAY

Sample Collected on (SCT) : 13 Jan 2025 20:47
Sample Received on (SRT) : 15 Jan 2025 01:20
Report Released on (RRT) : 15 Jan 2025 18:41
Sample Type : SERUM
Labcode : 1401002947/A4564
Barcode : CY002739

Renuka

Dr Renuka MD(Path)

Arshiya

Dr Arshiya MD(Path)

PROCESSED AT :

Thyrocare

D-37/1, TTC MIDC, Turbhe,
Navi Mumbai-400 703



Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703 9870666333 wellness@thyrocare.com

First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation[#]

NAME : MANASA ANUPA (28Y/F)
REF. BY : DR VISHWA BHARATHI MBBS DGO
TEST ASKED : QUADRUPLE MARKER SECOND TRIMESTER 14-22
WEEK, T3-T4-USTSH

SAMPLE COLLECTED AT :
(5053270516), BHAVITHA LABORATORY, DR. MD
SHANKAR LINE, OPP OLD SAI HOSPITAL, ARAVIND
NAGAR, JAGTIAL, TELANGANA, 505327

TEST NAME	TECHNOLOGY	VALUE	UNITS
UNCONJUGATED ESTRIOL - uE3	C.L.I.A	0.35	ng/mL
Bio. Ref. Interval. :-			

Males and Non pregnant Females : < 2.0

Pregnancy:

Weeks Ranges

16 Weeks : 0.30-1.05

18 Weeks : 0.63-2.30

34 weeks : 5.3-18.3

35 Weeks : 5.2 -26.4

36 Weeks : 8.2-28.1

37 Weeks : 8.0-30.1

38 Weeks : 8.6-38.0

39 Weeks : 7.2-34.3

40 Weeks : 9.6-28.9

Clinical Significance :

There is considerable patient-to-patient variability: The reference range for a given gestational age may encompass Estriol levels from 50 to 200 percent of the median for that age. Hence the pattern generated by serial determination is of greater significance than the results of isolated measurements. Persistently low or rapidly falling Estriol levels suggest fetal distress. Estriol concentration are subject to diurnal and episodic variation; Please refer serum levels to a baseline, Defined for the patient as either the average or the highest of her three most recent Estriol results.

Specifications: Precision: Intra assay (%CV): 10.75, Inter assay (%CV): 6.15, Sensitivity: 0.017 ng/mL

Reference : Teetz Chapter 45

Please correlate with clinical conditions.

Method:- Competitive binding immunoenzymatic assay

Sample Collected on (SCT) : 13 Jan 2025 20:47
Sample Received on (SRT) : 15 Jan 2025 01:20
Report Released on (RRT) : 15 Jan 2025 18:41
Sample Type : SERUM
Labcode : 1401002947/A4564
Barcode : CY002739

Renuka

Dr Renuka MD(Path)

Arshiya

Dr Arshiya MD(Path)

PROCESSED AT :**Thyrocare**D-37/1, TTC MIDC, Turbhe,
Navi Mumbai-400 703

Tests you can trust

Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703 9870666333 wellness@thyrocare.com

First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation[#]

NAME : MANASA ANUPA (28Y/F) **SAMPLE COLLECTED AT :**
REF. BY : DR VISHWA BHARATHI MBBS DGO (5053270516), BHAVITHA LABORATORY, DR. MD SHANKAR
TEST ASKED : QUADRUPLE MARKER SECOND TRIMESTER 14-22 LINE, OPP OLD SAI HOSPITAL, ARAVIND NAGAR,
WEEK, T3-T4-USTSH JAGTIAL, TELANGANA, 505327

TEST NAME	TECHNOLOGY	VALUE	UNITS	Bio. Ref. Interval.
TOTAL TRIIODOTHYRONINE (T3)	E.C.L.I.A	208	ng/dL	80-200
TOTAL THYROXINE (T4)	E.C.L.I.A	14	µg/dL	4.8-12.7
TSH - ULTRASENSITIVE	E.C.L.I.A	2.12	µIU/mL	0.54-5.30

The Biological Reference Ranges is specific to the age group. Kindly correlate clinically.**Method :**

T3, T4 - Fully Automated Electrochemiluminescence Competitive Immunoassay

USTSH - Fully Automated Electrochemiluminescence Sandwich Immunoassay

Pregnancy reference ranges for TSH/USTSH :

Trimester || T3 (ng/dl) || T4 (µg/dl) || TSH/USTSH (µIU/ml)

1st || 83.9-196.6 || 4.4-11.5 || 0.1-2.5

2nd || 86.1-217.4 || 4.9-12.2 || 0.2-3.0

3rd || 79.9-186 || 5.1-13.2 || 0.3-3.5

References :

1. Carol Devilia, C I Parhon. First Trimester Pregnancy ranges for Serum TSH and Thyroid Tumor reclassified as Benign. Acta Endocrinol. 2016; 12(2) : 242 - 243

2. Kulhari K, Negi R, Kalra DK et al. Establishing Trimester specific Reference ranges for thyroid hormones in Indian women with normal pregnancy : New light through old window. Indian Journal of Contemporary medical research. 2019; 6(4)

Disclaimer : Results should always be interpreted using the reference range provided by the laboratory that performed the test. Different laboratories do tests using different technologies, methods and using different reagents which may cause difference. In reference ranges and hence it is recommended to interpret result with assay specific reference ranges provided in the reports. To diagnose and monitor therapy doses, it is recommended to get tested every time at the same Laboratory.

Sample Collected on (SCT) : 13 Jan 2025 20:47
Sample Received on (SRT) : 15 Jan 2025 01:20
Report Released on (RRT) : 15 Jan 2025 18:41
Sample Type : SERUM
Labcode : 1401002947/A4564
Barcode : CY002739

Dr Renuka MD(Path)

Dr Arshiya MD(Path)
Page : 5 of 7

9 out of 10 Doctors Trust that Thyrocare Reports are Accurate & Reliable

Second Trimester Screening results

Patient data

Name and surname:	MANASA ANUPA	Weight:	83 Kg.
Lab ID:	CY002739	Height:	N/I
Race/Ethnicity:	INDIAN	Diabetes:	No
Date of birth:	30-10-1996 (28 years in the DoB)	Smoker:	No
Type of Pregnancy:	Spontaneous	Ovulation Ind.:	No
Prev. Obstetric History:	None	Referral Center:	A4564
Prenatal Software:	SSDWLAB6	Referral Doctor:	DR VISHWA BHARATHI

Biochemical data

Sample date:	13-01-2025	Gestational age:	14 weeks and 2 days
Sample ID:	CY002739		
Alpha-fetoprotein:	23.7 IU/ml	1.38 MoM	
hCG + beta:	40360 mIU/ml	1.35 MoM	
Unconjugated Oestriol:	0.35 ng/ml	0.58 MoM	
Inhibin-A:	267.1 pg/ml	1.87 MoM	

Risk report (At term)

Risk type	Probability	Result	Graphic representation
NTD:	No	Low Risk	No
Trisomy 21 age risk:	1/1101		1/1101
Trisomy 21:	1/943	Low Risk	1/943 250
Trisomy 18/13:	1/31043	Low Risk	1/31043 250

Observations

Low Risk.

NOTE: Second Trimester test uses assays for maternal serum alpha fetoprotein (AFP), Beta subunit of human chorionic gonadotropin (B-HCG), unconjugated estriol (uE3) for Triple test, and is Inhibin A is add for Quad test combined with patient specific data including patient age or weeks of pregnancy(WOP) weight, gestational age, number of fetus, previous bad obstetric history, medical history, information about IVF pregnancy, and demographics to calculate the numerical risk for fetal Down syndrome, Edward syndrome and neural tube defects. It uses a sophisticated software program called SsdwLab6, which works on a statistical database to calculate this risk, and hence any risk indicated should not be considered to be a confirmatory evidence of fetal risk. A risk indicated only says that further investigations are needed before a decision is taken and therefore the report should be interpreted in light of other clinical and laboratory evidences.

- The risk calculations are statistical approaches and have limited diagnostic value.
- The calculated risk by the software depends on the accuracy of USG details and patient details provided.
- Participants in UKAS-proficiency testing (EQAS) for maternal serum markers.
- The laboratory can not be held responsible for their impact on the risk assessment. Calculated risks have no diagnostic value.
- The screening risk estimates final risk using biochemical parameters results, maternal demographic characteristics, and maternal medical and obstetric history. The risk calculation is optimal when accurate critical information is provided and incorrect information ((TRF/ U.S scan report) may significantly alter the risk assessment.
- Risks cannot be calculated for triplets or higher order gestations. In twin pregnancies with fetal demise (vanishing twins) risk estimation can be calculated but may be unreliable.

9 out of 10 Doctors Trust that Thyrocare Reports are Accurate & Reliable

- Comparison with other screening software's and assay methodologies may give varying risk assessments. Risk assessment at term and sampling are both valid ways of estimating risk, but the risk score between the two varies because a correction factor of intrauterine mortality is applied for risk at sampling which is not taken into consideration while computing risk at term.
- Sophisticated software program SsdwLab6 works on statistical database to calculate this risk and hence any risk indicated should not be considered to be confirmatory evidence of fetal risk.
- This is a screening report and will need further confirmatory tests for diagnosis. Kindly consult your doctor for further.

Anomaly	Risk Ratio	Risk Categorization
Down's Syndrome (Trisomy 21)	> 1:250	Low Risk
	< 1:250	High Risk
Trisomy 13/18	> 1:250	Low Risk
	< 1:250	High Risk
NTD	No	Low Risk
	Yes	High Risk

Authorized by:

Adinath Suryavanshi

Printing date:

15-01-2025



 Dr. Arshiya Bose
 MBBS, MD Pathology

CONDITIONS OF REPORTING

- ✓ The reported results are for information and interpretation of the referring doctor only.
- ✓ It is presumed that the tests performed on the specimen belong to the patient; named or identified.
- ✓ Results of tests may vary from laboratory to laboratory and also in some parameters from time to time for the same patient.
- ✓ Should the results indicate an unexpected abnormality, the same should be reconfirmed.
- ✓ Only such medical professionals who understand reporting units, reference ranges and limitations of technologies should interpret results.
- ✓ This report is not valid for medico-legal purpose.
- ✓ Neither Thyrocare, nor its employees/representatives assume: (a) any liability, responsibility for any loss or damage that may be incurred by any person as a result of presuming the meaning or contents of the report, (b) any claims of any nature whatsoever arising from or relating to the performance of the requested tests as well as any claim for indirect, incidental or consequential damages. The total liability, in any case, of Thyrocare shall not exceed the total amount of invoice for the services provided and paid for.
- ✓ Thyrocare Discovery video link :- <https://youtu.be/nbdYeRgYyQc>

EXPLANATIONS

- ✓ Majority of the specimen processed in the laboratory are collected by Pathologists and Hospitals we call them as "Clients".
- ✓ **Name** - The name is as declared by the client and recored by the personnel who collected the specimen.
- ✓ **Ref.Dr** - The name of the doctor who has recommended testing as declared by the client.
- ✓ **Labcode** - This is the accession number in our laboratory and it helps us in archiving and retrieving the data.
- ✓ **Barcode** - This is the specimen identity number and it states that the results are for the specimen bearing the barcode (irrespective of the name).
- ✓ **SCP** - Specimen Collection Point - This is the location where the blood or specimen was collected as declared by the client.
- ✓ **SCT** - Specimen Collection Time - The time when specimen was collected as declared by the client.
- ✓ **SRT** - Specimen Receiving Time - This time when the specimen reached our laboratory.
- ✓ **RRT** - Report Releasing Time - The time when our pathologist has released the values for Reporting.
- ✓ **Reference Range** - Means the range of values in which 95% of the normal population would fall.

SUGGESTIONS

- ✓ Values out of reference range requires reconfirmation before starting any medical treatment.
- ✓ Retesting is needed if you suspect any quality shortcomings.
- ✓ Testing or retesting should be done in accredited laboratories.
- ✓ For suggestions, complaints, clinical support or feedback, write to us at **customersupport@thyrocare.com** or call us on **022-3090 0000**

Preventive Healthcare is now at your fingertips!



Download Thyroapp Now



Launching

Jaanh

For a closer look at your health with

Doctor-Curated Specialised Packages All Under One Roof

 Heart	 Fever	 Cancer	 Women's - Reproductive Health	
 Thyroid	 Diabetes	 STDs	 Skin Care	 Hair Fall

 **Thyrocare**
Tests you can trust

*T&C Apply, #As on 5th December 2024, *As per a survey on doctors' perception of laboratory diagnostics (IJARIIT,2023)